Dynamic Hyperglycemic Patterns Predict Adverse Outcomes in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy.
acute ischemic stroke
hyperglycemia
large vessel occlusion
mechanical thrombectomy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Jun 2020
20 Jun 2020
Historique:
received:
05
05
2020
revised:
18
06
2020
accepted:
18
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
Admission hyperglycemia impairs outcome in acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT). Since hyperglycemia in AIS represents a dynamic condition, we tested whether the dynamic patterns of hyperglycemia, defined as blood glucose levels > 140 mg/dl, affect outcomes in these patients. We retrospectively analyzed data of 200 consecutive patients with prospective follow-up. Based on blood glucose level, patients were distinguished into 4 groups: (1) persistent normoglycemia; (2) hyperglycemia at baseline only; (3) hyperglycemia at 24-h only; and (4) persistent (at baseline plus at 24-h following MT) hyperglycemia. AIS patients with persistent hyperglycemia have a significantly increased risk of poor functional outcome (OR 6.89, 95% CI 1.98-23.94, Our study suggests that it is useful to perform the prolonged monitoring of glucose levels lasting 24-h after MT.
Sections du résumé
BACKGROUND
BACKGROUND
Admission hyperglycemia impairs outcome in acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT). Since hyperglycemia in AIS represents a dynamic condition, we tested whether the dynamic patterns of hyperglycemia, defined as blood glucose levels > 140 mg/dl, affect outcomes in these patients.
METHODS
METHODS
We retrospectively analyzed data of 200 consecutive patients with prospective follow-up. Based on blood glucose level, patients were distinguished into 4 groups: (1) persistent normoglycemia; (2) hyperglycemia at baseline only; (3) hyperglycemia at 24-h only; and (4) persistent (at baseline plus at 24-h following MT) hyperglycemia.
RESULTS
RESULTS
AIS patients with persistent hyperglycemia have a significantly increased risk of poor functional outcome (OR 6.89, 95% CI 1.98-23.94,
CONCLUSIONS
CONCLUSIONS
Our study suggests that it is useful to perform the prolonged monitoring of glucose levels lasting 24-h after MT.
Identifiants
pubmed: 32575739
pii: jcm9061932
doi: 10.3390/jcm9061932
pmc: PMC7355777
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurology. 2005 Oct 25;65(8):1169-74
pubmed: 16247041
Stroke. 2014 Jun;45(6):1881-6
pubmed: 24743441
J Neurol. 2018 Dec;265(12):2875-2880
pubmed: 30276519
Crit Care. 2013 Mar 06;17(2):305
pubmed: 23470218
Stroke. 2017 May;48(5):1299-1305
pubmed: 28389610
JAMA. 2019 Jul 23;322(4):326-335
pubmed: 31334795
Stroke. 2016 Jun;47(6):1584-92
pubmed: 27217508
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Diabetes Care. 2009 Apr;32(4):617-22
pubmed: 19131465
Cerebrovasc Dis. 2011;31(1):83-92
pubmed: 21079397
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Eur J Neurol. 2002 May;9(3):297-301
pubmed: 11985639
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396
Diabetes Res. 1987 Sep;6(1):47-9
pubmed: 3690957
Stroke. 2017 Jul;48(7):1932-1940
pubmed: 28526762
Front Neurol. 2019 Sep 18;10:1003
pubmed: 31620074
J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1668-1673
pubmed: 30890395
JAMA. 1995 Oct 4;274(13):1017-25
pubmed: 7563451
Mol Neurobiol. 2019 Mar;56(3):1883-1896
pubmed: 29974394
N Engl J Med. 2015 Jun 11;372(24):2285-95
pubmed: 25882376
J Neurol Sci. 1976 Oct;29(2-4):267-75
pubmed: 978211
J Thromb Thrombolysis. 2017 Aug;44(2):203-209
pubmed: 28702769
J Neurol Sci. 2020 Feb 15;409:116588
pubmed: 31837537
Am J Med Sci. 2016 Apr;351(4):380-6
pubmed: 27079344
Ann Neurol. 2011 Oct;70(4):583-90
pubmed: 22002675
Stroke. 2016 Jan;47(1):120-7
pubmed: 26658447
Int J Stroke. 2018 Oct;13(8):857-862
pubmed: 30019627
Stroke. 2020 Apr;51(4):1199-1206
pubmed: 32156204
Lancet. 2000 Mar 4;355(9206):773-8
pubmed: 10711923
Stroke. 2003 Sep;34(9):2208-14
pubmed: 12893952
PLoS One. 2014 Apr 18;9(4):e94364
pubmed: 24747428
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
J Clin Med. 2018 Dec 05;7(12):
pubmed: 30563115
Eur J Neurol. 2019 Jul;26(7):1019-1027
pubmed: 30868681
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
Stroke. 2019 Mar;50(3):690-696
pubmed: 30777000
J Neurointerv Surg. 2018 Feb;10(2):112-117
pubmed: 28289148
Ther Adv Neurol Disord. 2019 Mar 27;12:1756286419835708
pubmed: 30944585
Stroke. 2008 Oct;39(10):2749-55
pubmed: 18703813
Stroke. 2001 Oct;32(10):2426-32
pubmed: 11588337
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Stroke. 2009 Feb;40(2):562-8
pubmed: 19095970
Int J Neurosci. 2016;126(1):67-9
pubmed: 25562545
Stroke. 2004 Jan;35(1):147-50
pubmed: 14657446